• Explore /
  • Poster
  • / Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

Abstract Poster

Authors

Sumanta Pal

Sumanta K. Pal

Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA

Sumanta K. Pal , Javier Puente , Daniel Yick Chin Heng , Hilary Glen , Piotr Koralewski , Daniil Stroyakovskiy , Boris Alekseev , Francis Parnis , Daniel Castellano , Tudor Ciuleanu , Jae-Lyun Lee , Kaisa Sunela , Karen O'Hara , Terri A. Binder , Lixian Peng , Alan D. Smith , Sun Young Rha

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03173560

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 307)

DOI

10.1200/JCO.2021.39.6_suppl.307

Abstract #

307

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Chung-Han Lee

First Author: Yongkang Xu

First Author: Lorenza Rimassa

First Author: Joshua E. Reuss